122 related articles for article (PubMed ID: 23597579)
21. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives.
Tan SL; Liao C; Lucas MC; Stevenson C; DeMartino JA
Pharmacol Ther; 2013 May; 138(2):294-309. PubMed ID: 23396081
[TBL] [Abstract][Full Text] [Related]
22. Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.
Niemann CU; Mora-Jensen HI; Dadashian EL; Krantz F; Covey T; Chen SS; Chiorazzi N; Izumi R; Ulrich R; Lannutti BJ; Wiestner A; Herman SEM
Clin Cancer Res; 2017 Oct; 23(19):5814-5823. PubMed ID: 28645939
[No Abstract] [Full Text] [Related]
23. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
Paesler J; Gehrke I; Gandhirajan RK; Filipovich A; Hertweck M; Erdfelder F; Uhrmacher S; Poll-Wolbeck SJ; Hallek M; Kreuzer KA
Clin Cancer Res; 2010 Jul; 16(13):3390-8. PubMed ID: 20570929
[TBL] [Abstract][Full Text] [Related]
24. Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors.
Tavolaro S; Chiaretti S; Messina M; Peragine N; Del Giudice I; Marinelli M; Santangelo S; Mauro FR; Guarini A; Foà R
Leuk Res; 2010 Jun; 34(6):733-41. PubMed ID: 20036005
[TBL] [Abstract][Full Text] [Related]
25. Mechanistic insights into the antileukemic activity of hyperforin.
Billard C; Merhi F; Bauvois B
Curr Cancer Drug Targets; 2013 Jan; 13(1):1-10. PubMed ID: 22924417
[TBL] [Abstract][Full Text] [Related]
26. Incorporating targeted agents into future therapy of chronic lymphocytic leukemia.
Pallasch CP; Hallek M
Semin Hematol; 2014 Jul; 51(3):235-48. PubMed ID: 25048787
[TBL] [Abstract][Full Text] [Related]
27. Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.
Balakrishnan K; Gandhi V
Expert Opin Investig Drugs; 2012 Apr; 21(4):409-23. PubMed ID: 22409342
[TBL] [Abstract][Full Text] [Related]
28. The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia.
Shanafelt TD; Kay NE
Semin Oncol; 2006 Apr; 33(2):174-85. PubMed ID: 16616064
[TBL] [Abstract][Full Text] [Related]
29. Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia.
Davids MS; Brown JR
Hematol Oncol Clin North Am; 2013 Apr; 27(2):329-39. PubMed ID: 23561476
[TBL] [Abstract][Full Text] [Related]
30. NF-kappaB as a therapeutic target in chronic lymphocytic leukemia.
Lopez-Guerra M; Colomer D
Expert Opin Ther Targets; 2010 Mar; 14(3):275-88. PubMed ID: 20148715
[TBL] [Abstract][Full Text] [Related]
31. Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.
Hartmann TN; Pleyer L; Desch P; Egle A; Greil R
Discov Med; 2009 Oct; 8(42):157-64. PubMed ID: 19833065
[TBL] [Abstract][Full Text] [Related]
32. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
[TBL] [Abstract][Full Text] [Related]
33. Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.
Maffei R; Colaci E; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
Crit Rev Oncol Hematol; 2016 Jan; 97():291-302. PubMed ID: 26454471
[TBL] [Abstract][Full Text] [Related]
34. Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option.
Ringshausen I; Peschel C; Decker T
Leuk Lymphoma; 2005 Jan; 46(1):11-9. PubMed ID: 15621776
[TBL] [Abstract][Full Text] [Related]
35. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
36. Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis.
Stamatopoulos B; Meuleman N; De Bruyn C; Mineur P; Martiat P; Bron D; Lagneaux L
Leukemia; 2009 Dec; 23(12):2281-9. PubMed ID: 19710697
[TBL] [Abstract][Full Text] [Related]
37. The CLL cell microenvironment.
Burger JA
Adv Exp Med Biol; 2013; 792():25-45. PubMed ID: 24014291
[TBL] [Abstract][Full Text] [Related]
38. Emerging drugs for chronic myeloid leukemia.
Cilloni D; Messa E; Rotolo A; Saglio G
Expert Opin Emerg Drugs; 2010 Jun; 15(2):175-84. PubMed ID: 20201747
[TBL] [Abstract][Full Text] [Related]
39. Receptor tyrosine kinase-like orphan receptor 1 (ROR-1): An emerging target for diagnosis and therapy of chronic lymphocytic leukemia.
Aghebati-Maleki L; Shabani M; Baradaran B; Motallebnezhad M; Majidi J; Yousefi M
Biomed Pharmacother; 2017 Apr; 88():814-822. PubMed ID: 28160756
[TBL] [Abstract][Full Text] [Related]
40. Kinase inhibitors overachieve in CLL.
Garber K
Nat Rev Drug Discov; 2014 Mar; 13(3):162-4. PubMed ID: 24549135
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
